Human immunodeficiency virus (HIV) infected patients using our Intranasal Light therapy devices are experiencing distinct improvements in their condition. The promise and expectation out of this are high but they count for nothing if there is no scientific basis or the presence of credible evidence. What is the evidence and scientific basis behind Intranasal Light Therapy working for them?
The commonly accepted key factors in determining the health of the HIV-infected patient are:
- CD4*T cell count
- Viral load
For most patients the critical factor is in the CD4*T cell count because if that falls below 250 per microlitre (µL), the disease progresses to “full-blown” AIDS (acquired immune deficiency syndrome). In many cases, the untreated victim dies within a year from an opportunistic disease such as a cancer, pneumonia, tuberculosis, gastrointestinal infections, etc. Today, the widely recognised optimal CD4*T cell count is 500/µL.
The viral load (measured in RNA copies per milliliter of blood plasma). A viral load greater than 100,000 copies/mL of blood could be an indicator of the condition developing into AIDS within five years.
Our anecdotal evidence
We have two HIV-infected patients who can attribute the improvement in their conditions to the use of the Intranasal Light Therapy devices. Patient A (who is trying out various non-drug therapies) uses a low level laser version and sees his CD4*T cell count moving up from about 390/µL in June 2011 to about 600/µL in November 2011. He routinely treats himself with 2 daily session of 25 minutes each. See the figure below.
Furthermore, Patient A’s viral load has dropped from about 104,000 copies/mL in June 2011 to about 38,000 copies/mL in November 2011; now well below the danger level of 100,000 copies/mL.
Patient B who is on antiretroviral drugs for several years and been experiencing a downward trend in his CD4*T cell count, which of course has been worrying. That has since been positively interrupted by his use of the Intranasal Light Therapy device. Since the start of his daily self-treatment of at least once a day 25 minutes with the device (the non-laser/LED version in this case), his CD4*T cell count has increased from about 450/µL to about 650/µL.
Still, 2 swallows do not make a summer, and we are hoping to obtain support to put our technology for testing under clinical conditions. So we seek scientific and evidential support.
The evidence of CD4*T cell proliferation with Intranasal Light Therapy
Several Chinese laboratories have examined the effect of intravenous blood irradiation on the immune system. In 1997, a group reported that in their study on 23 patients, the CD4*T cell count increased significantly when it was measured after the tenth treatment.
Our own findings as well as clinical studies establish that the outcomes of using the older intravenous blood irradiation is the same as Intranasal Light Therapy. Therefore one would expect the results to be replicable with our Intranasal Light Therapy method.
Both laser and non-laser (LED) produce the same outcome
The outcomes of both the low level laser device and the LED devices are positive and similar. We would expect this to be so, based on the understanding of photobiology that the cellular response is based on the correct combination of the wavelength of light (not the coherency of a laser) and the dosage.
The underlying biomechanism
During an Intranasal Light Therapy treatment, the oxygen molecule is raised to a higher energy state when it absorbs the photon. This excited molecule undergoes a change by having an unpaired electron (becoming a singlet oxygen) which then sends a “redox signal” to the body to neutralize the free radical. The process of homeostasis restoration would result in the proliferation of CD4*T cells as well as other components of the immune system. The chosen dosage for Intranasal Light Therapy is large enough to induce an action but not sufficient to cause damage. An expanded exposition of this theory can be viewed on a separate page. The role of the redox signalling molecule in stimulating the immune system is now represented by a large enough body of evidence. That would include the creation of additional leukocytes or white blood cells of various types, including the CD4*T cells. It is believed that this signalling process would also lead to other known complementary processes that add to the fight against HIV, such as the stimulation of certain enzyme and stem cell activities as expounded further below.
Having established the molecular mechanism above, and based on the body of work of research into low level laser therapy and blood irradiation over the years, we can construct the various pathways that they body takes in healing a HIV condition with Intranasal Light Therapy. We can present three pathways that have increasing evidential support: 1. restoration of redox homeostasis, 2. specific enzyme (SIRT1) activity and 3. mesenchymal stem cell stimulation.
Restoration of redox homeostasis
Redox homeostasis is a state in which oxidants and antioxidants in the body are balanced. Oxidants in the form of reactive oxygen species (ROS) are constantly created by the activities of the body, and given a spike when there is an inflammation. We fall ill when the body is unable to reduce the oxidative stress to restore homeostasis. However, the process of restoring homeostasis enhances the immune system which includes the proliferation of CD4*T cells. The ROS act as signalling molecules to call on the restoration or healing process. When light in the visible red spectrum illuminates at a low dosage illuminates the bloodstream, it excites the release of singlet oxygen (which is a ROS), which signals to the body to heal without causing any harm on its own under low dose.
Control through SIRT1 activity
It has been found that the human enzyme, diacetylase sirtuin 1 (SIRT1) can control HIV replication by interrupting its gene structure.  Intranasal light therapy has been found to increase SIRT1 activity, and therefore can be used to control the HIV condition of a patient.
Control through improved mesenchymal stem cell activity
The spread of HIV in the body is based upon the former’s microRNA activity. It had been found that improved mesenchymal stem cell (MSC) activity can restrict the microRNA based replication of HIV. Tests on mice have shown that low level irradiation of the bone marrow can regulate the role of the MSC’s. It can therefore be hypothesized that in the same way, the systemic effect from Intranasal Light Therapy would modulate MSC-related miRNAs and consequently, HIV-1-related miRNAs.
In any event, a high incidence of decreased bone mineral density has been associated with HIV infection. Irradiation with light therapy, whether directly at the bone marrow or systemically with the Intranasal Light Therapy method, should alleviate the HIV attack on bone material density.
In conclusion, there is sufficient scientific bases and clinical evidence to suggest that Intranasal Light Therapy promises to be a viable method to control HIV in an infected person. We aim to conduct a randomized double-blind placebo-controlled study in the future to verify this hypothesis.
Implications for the future
The expected outcome with a serious viral infection such as HIV has profound implications on what Intransal Light Therapy can achieve in the vast sphere of viral infection. It is a complex science, especially in dealing with increasing rapid viral mutations to resist therapeutic drugs. Notwithstanding, we can now promote the concept of relying on our own bodies as the greatest medical devices. Modern understanding of the immune system realizes that our own complex leukocyte activities are also constantly coping with new viral strains, and given time, can often come out on top. More importantly, our bodies do not introduce dilapidating side effects that drugs often do.
Intranasal Light Therapy simplifies the process by many factors by simply stimulating the body to do the job on its own. In the end, we encourage the patient to take ownership of his condition in the simplest and cost-effective way possible.
1. Xu Q, Shi GY, Hua SB, Wang RY, Fen Z, Yu Q and Wu W (1997). Semiconductor laser irradiation on human peripheral blood T lymphocytes and NK cells in immune system regulation. Laser Biology; 1997 (03). (In Chinese).
2. Smith, K C (2005), Laser (and LED) Therapy Is Phototherapy. Phototomedicine and Laser Surgery; 23 (78-80).
3. Pagans S, Pedal A, North BJ, Kaehlcke K, Marshall BL, et al. (2005) SIRT1 Regulates HIV Transcription via Tat Deacetylation. PLoS Biol 3(2).
4. Liu TCY, Wu DF, Gu ZQ, Wu M (2010). Applications of intranasal low intensity laser therapy in sports medicine. Journal of Innovation in Optical Health Science. 3(1): 1-16.
5. Strebel K, Luban J, Jeang KT (2009). Human cellular restriction factors that target HIV-1 replication. BMC Med. 2009 Sep 16;7:48.
6. Silva WA Jr, Covas DT, Panepucci RA, Proto-Siqueira R, Siufi JL, Zanette DL, Santos AR, Zago MA (2003). The profile of gene expression of human marrow mesenchymal stem cells. Stem Cells. 2003;21(6):661-9.
7. Tuby H, Maltz L, Oron U (2011). Induction of autologous mesenchymal stem cells in the bone marrow by low-level laser therapy has profound beneficial effects on the infarcted rat heart. Lasers Surg Med. 2011 Jul;43(5):401-9.
8. Cotter EJ, Ip HSM, Powderly WG,1 and Doran PP (2008). Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. BMC Musculoskelet Disord. 2008; 9: 33.